Other Events ·
On August 18, 2026, Emergent BioSolutions Inc. received Modification No. 21 to its BARDA AV7909 Contract, securing an…
EBSEmergent BioSolutions Inc.
On August 18, 2026, Emergent BioSolutions Inc. received Modification No. 21 to its BARDA AV7909 Contract, securing an additional $24 million in funding for the procurement of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted). This contract modification supports anthrax preparedness efforts and builds upon previous government agreements, including a recent delivery order valued at up to $21.5 million for BioThrax supplies. The company operates in the biopharmaceutical industry, developing and manufacturing medical countermeasures against biological threats.